STEP 1
2021
Once-Weekly Semaglutide in Adults with Overweight or Obesity
In 1,961 adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide 2.4 mg weekly reduced body weight at 68 weeks compared with placebo.
Result
difference (pp)-12.4P < 0.001
Also reported: ≥15 % loss in 50 % of the semaglutide group.
- Subtopic
- Semaglutide for obesity
- Design
- Double-blind RCT, 68 weeks
- Relevance
- Important: one of several pillars.
- Cited in
- ACC/AHA 2026 CKM
- Also listed in
- Diabetes & cardiometabolic
- Source
- Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.doi 10.1056/NEJMoa2032183
Discussion & critique
Basis of the Wegovy approval. STEP 4 later showed weight regain on withdrawal, framing obesity as a chronic disease requiring continuous therapy.